Page last updated: 2024-08-26

sr141716 and Obesity, Morbid

sr141716 has been researched along with Obesity, Morbid in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (66.67)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aouad, L; Bell-Anderson, KS; Caterson, ID; Farrell, GC; Larter, CZ; Phuyal, J; Sanz, FR; Williams, H1
Botha, AJ; Crook, MA; Dar, A; McMahon, Z; Oben, J; Pendleton, S; Wierzbicki, AS1
Bedros, JR; Medvegy, M; Pados, G; Simonyi, G1
Amsterdam, EA1
Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W1
Boekholdt, SM; Jukema, JW; Peters, RJ1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H1
Nau, JY1
Al-Zaman, Y; Aylwin, S1

Reviews

4 review(s) available for sr141716 and Obesity, Morbid

ArticleYear
[The pharmacological treatment of obesity: past, present and future].
    Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10

    Topics: Amides; Anti-Obesity Agents; Anticonvulsants; Antidepressive Agents; Basal Metabolism; Benzazepines; Benzoxazines; Body Mass Index; Bridged Bicyclo Compounds, Heterocyclic; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Combined Modality Therapy; Cyclobutanes; Dexfenfluramine; Fatty Acids; Female; Fenfluramine; Glucagon-Like Peptide 1; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Leptin; Life Style; Liraglutide; Male; Norepinephrine; Obesity; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Pyridines; Receptor, Melanocortin, Type 4; Rimonabant; Satiation; Serotonin; Sodium-Glucose Transport Proteins; Sucrose; Thyroid Hormones

2012
[Obesity in adults].
    Praxis, 2007, Oct-17, Volume: 96, Issue:42

    Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss

2007
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47

    Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss

2007
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide

2008

Other Studies

5 other study(ies) available for sr141716 and Obesity, Morbid

ArticleYear
Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
    International journal of obesity (2005), 2011, Volume: 35, Issue:12

    Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose Intolerance; Glucose Tolerance Test; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant

2011
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.
    International journal of clinical practice, 2011, Volume: 65, Issue:6

    Topics: Adult; Biomarkers; Cannabinoid Receptor Modulators; Cholesterol; Fatty Liver; Female; Humans; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Safety-Based Drug Withdrawals; Triglycerides; Weight Loss

2011
Rimonabant: unique and promising.
    Preventive cardiology, 2005,Summer, Volume: 8, Issue:3

    Topics: Animals; Appetite; Cannabinoid Receptor Antagonists; Global Health; Humans; Incidence; Obesity, Morbid; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome

2005
[New drugs; rimonabant].
    Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47

    Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss

2007
[Antiobesity drugs--new limitations].
    Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135

    Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss

2007